Search clinical trials for: Treprostinil Diolamine

Total 4679 results

United Therapeutics
Lung Biotechnology PBC

Recruiting

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (ARTISAN)

Pulmonary Arterial Hypertension

United States
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
University Medicine Greifswald
OMT GmbH & Co. KG

Unknown

Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension (LPS-II)

Pulmonary Arterial Hypertension | PAH

Germany
United Therapeutics

Terminated

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

Peripheral Vascular Disease

United States
Liquidia Technologies, Inc.
FGK Clinical Research GmbH

Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Pulmonary Arterial Hypertension

France, Germany
United Therapeutics

Withdrawn

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Medtronic Cardiac Rhythm and Heart Failure
United Therapeutics

Withdrawn

Implantable System for Remodulin Post-Approval Study (ISR PAS)

Pulmonary Arterial Hypertension
United Therapeutics
Lung Biotechnology PBC

Completed

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH (PRN)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Withdrawn

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension
United Therapeutics

Completed

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Pulmonary Arterial Hypertension

United States
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

PAH

United States
Southern Arizona Vascular Institute
Southern Illinois University

Unknown

UT-15C SR in the Treatment of Critical Limb Ischemia

Critical Limb Ischemia

United States
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Healthy Volunteers

United States
University Hospital, Grenoble
University Grenoble Alps; Linksium

Completed

Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study (TISSUE-PoC)

Scleroderma, Systemic

France
United Therapeutics

Completed

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Pulmonary Hypertension

United States
United Therapeutics

Terminated

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel, Argentina, Puerto Rico
United Therapeutics

Completed

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States
United Therapeutics

Terminated

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Hypertension, Pulmonary

United States
United Therapeutics

Completed

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (DISTOL-1)

Systemic Sclerosis | Scleroderma

United States, Canada, United Kingdom
University Hospital, Grenoble

Terminated

Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers (InTREPiD)

Diabetic Foot Ulcer

France
Ochsner Health System
United Therapeutics

Completed

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

Critical Limb Ischemia

United States
Shanghai Jiao Tong University School of Medicine

Completed

Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

Pulmonary Hypertension
University of California, Los Angeles
United Therapeutics

Withdrawn

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Congenital Heart Disease

United States
United Therapeutics

Completed

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, United Kingdom, Canada, Spain, Australia, Israel, Germany, Belgium, France, Austria, Italy, Poland, Ireland, Netherlands
United Therapeutics
Asian Clinical Trials

Terminated

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension (TRUST-1)

Pulmonary Arterial Hypertension

India
University Hospital, Grenoble

Completed

Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers (INFLUX-IT-VS)

Healthy

France
United Therapeutics

Completed

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Pulmonary Arterial Hypertension

United States
University of North Carolina, Chapel Hill
United Therapeutics

Terminated

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Respiratory Distress Syndrome, Adult

United States
University of Florida
United Therapeutics

Recruiting

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (SAPPHIRE)

Interstitial Lung Disease | Sarcoidosis | Precapillary Pulmonary Hypertension

United States
United Therapeutics

Completed

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso (BREEZE)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Terminated

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Hypertension, Pulmonary

United States
Inova Health Care Services

Terminated

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

Chronic Obstructive Pulmonary Disease (COPD)

United States
United Therapeutics

Completed

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Pulmonary Hypertension

United States
United Therapeutics

Completed

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United Therapeutics

Terminated

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Pulmonary Arterial Hypertension

United States
Pharmosa Biopharm Inc.
PPD

Completed

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Pulmonary Arterial Hypertension

United States
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
United Therapeutics
University of Pittsburgh Medical Center

Withdrawn

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Liver Transplant

United States
University of Arizona

Unknown

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) (TRIUMPH)

Pulmonary Hypertension

United States, Israel, Austria, United Kingdom, Belgium, France, Germany, Ireland, Italy, Spain
Magdi H. Yacoub

Recruiting

Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension

Pulmonary Hypertension

Egypt
Jewish General Hospital

Withdrawn

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Pulmonary Arterial Hypertension

Canada
United Therapeutics

Completed

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) (RAPID)

Pulmonary Arterial Hypertension
Rajan Saggar
United Therapeutics

Completed

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

Idiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Interstitial Lung Disease

United States
United Therapeutics
University of California, Los Angeles; Emory University; Brigham and Women's... and other collaborators

Completed

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Pulmonary Arterial Hypertension | Pulmonary Hypertension | Portopulmonary Hypertension

United States
United Therapeutics

Completed

Remodulin® to Oral Treprostinil Transition

Pulmonary Arterial Hypertension

United States

3

Subscribe